Glaukos Gross Margin 2014-2025 | GKOS
Current and historical gross margin for Glaukos (GKOS) over the last 10 years. The current gross profit margin for Glaukos as of March 31, 2025 is %.
| Glaukos Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2025-03-31 | $0.41B | $0.31B | 75.56% |
| 2024-12-31 | $0.38B | $0.29B | 75.26% |
| 2024-09-30 | $0.36B | $0.28B | 76.18% |
| 2024-06-30 | $0.34B | $0.26B | 76.32% |
| 2024-03-31 | $0.33B | $0.25B | 76.07% |
| 2023-12-31 | $0.31B | $0.24B | 76.11% |
| 2023-09-30 | $0.30B | $0.23B | 75.91% |
| 2023-06-30 | $0.30B | $0.22B | 75.68% |
| 2023-03-31 | $0.29B | $0.22B | 75.78% |
| 2022-12-31 | $0.28B | $0.21B | 75.62% |
| 2022-09-30 | $0.29B | $0.22B | 75.79% |
| 2022-06-30 | $0.29B | $0.22B | 76.47% |
| 2022-03-31 | $0.29B | $0.23B | 76.87% |
| 2021-12-31 | $0.29B | $0.23B | 76.87% |
| 2021-09-30 | $0.29B | $0.22B | 76.19% |
| 2021-06-30 | $0.28B | $0.21B | 74.65% |
| 2021-03-31 | $0.24B | $0.16B | 68.07% |
| 2020-12-31 | $0.23B | $0.13B | 59.56% |
| 2020-09-30 | $0.22B | $0.13B | 59.63% |
| 2020-06-30 | $0.21B | $0.13B | 63.21% |
| 2020-03-31 | $0.24B | $0.18B | 73.22% |
| 2019-12-31 | $0.24B | $0.20B | 83.61% |
| 2019-09-30 | $0.23B | $0.20B | 86.73% |
| 2019-06-30 | $0.21B | $0.18B | 86.73% |
| 2019-03-31 | $0.20B | $0.17B | 86.67% |
| 2018-12-31 | $0.18B | $0.16B | 86.19% |
| 2018-09-30 | $0.17B | $0.15B | 86.39% |
| 2018-06-30 | $0.17B | $0.14B | 86.67% |
| 2018-03-31 | $0.16B | $0.14B | 87.12% |
| 2017-12-31 | $0.16B | $0.14B | 87.42% |
| 2017-09-30 | $0.15B | $0.13B | 86.67% |
| 2017-06-30 | $0.14B | $0.12B | 86.43% |
| 2017-03-31 | $0.13B | $0.11B | 85.16% |
| 2016-12-31 | $0.12B | $0.10B | 85.22% |
| 2016-09-30 | $0.10B | $0.09B | 85.29% |
| 2016-06-30 | $0.09B | $0.08B | 84.62% |
| 2016-03-31 | $0.08B | $0.07B | 83.75% |
| 2015-12-31 | $0.07B | $0.06B | 81.94% |
| 2015-09-30 | $0.07B | $0.05B | 77.27% |
| 2015-06-30 | $0.06B | $0.05B | 76.27% |
| 2015-03-31 | $0.05B | $0.04B | 76.92% |
| 2014-12-31 | $0.05B | $0.03B | 75.56% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $5.358B | $0.383B |
| Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally. | |||